

31 October 2012

ASX ANNOUNCEMENT

APPENDIX 4C - QUARTERLY CASH FLOW

Analytica Limited (the Company) presents its Appendix 4C for the quarter ended September 2012.

The Company held cash reserves at the end of the period of \$956,000.

Research and development expenditure (\$193k), staff costs (\$145k), and general overheads (\$89k) with receipt of R&D tax concession (\$158k) accounted for the bulk of the operating cash flows for the quarter.

The Company continues to have a line of credit of \$400,000 to ensure adequate funding of the Company.

The company's operations manager, Geoff Daly and director Warren Brooks are attending the Medica trade fair in Dusseldorf being held 13th to the 17th November. Medica is an international trade fair and congress for medical technology, electromedicine, laboratory equipment, diagnostics and drugs. This fair is an excellent platform to pursue distribution opportunities. Mr Daly will be returning via the United States for further burette distribution discussions.

An alternate strategy for entering the Latin American market has been deployed by Analytica. Specialist consultants have been commissioned to research the burette market and identify and engage distribution partners. An example of the potential of this market is that Brazil, now the 6th largest economy, has 7,800 hospitals with in excess of 810,000 beds. The board is most encouraged with the progress of this commission.

Medical Australia currently have representatives in Europe pursuing distribution opportunities.

For, and on behalf of the board,

Dr Michael Monsour

Chairman, Board of Directors

Analytica Limited (ASX:ALT) is an Australian company dedicated to the design, development and supply of Class I and IIa medical devices. Analytica's focus is on the product development and commercialisation of a range of medical devices.



Appendix 4C

Quarterly report for entities admitted on the basis of commitments

Introduced 31/3/2000. Amended 30/9/2001

Name of entity

Analytica Limited

ABN

12 006 464 866

Quarter ended ("current quarter")

30 September 2012

Consolidated statement of cash flows

Cash flows related to operating activities	Current quarter \$A'000	Year to date (3 months) \$A'000
1.1 Receipts from customers		
1.2 Payments for (a) staff costs	(145)	(145)
(b) advertising and marketing	-	-
(c) research and development	(193)	(193)
(d) leased assets	-	-
(e) other working capital	(89)	(89)
1.3 Dividends received	-	-
1.4 Interest and other items of a similar nature received	12	12
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Other-		
(a) Net sales income	-	-
(b) R & D Tax Concession	158	158
(c) Royalty Income	-	-
Net operating cash flows	(257)	(257)

+ See chapter 19 for defined terms.

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

	Current quarter \$A'000	Year to date (3 months) \$A'000
1.8 Net operating cash flows (carried forward)	(257)	(257)
Cash flows related to investing activities		
1.9 Payment for acquisition of:		
(a) businesses	-	-
(b) equity investments	-	-
(c) intellectual property	-	-
(d) physical non-current assets	(4)	(4)
(e) other non-current assets	-	-
1.10 Proceeds from disposal of:		
(a) businesses	-	-
(b) equity investments	-	-
(c) intellectual property	-	-
(d) physical non-current assets	-	-
(e) other non-current assets	-	-
1.11 Loans to other entities	-	-
1.12 Loans repaid by other entities	-	-
1.13 Other (purchase of Convertible Notes)	-	-
Net investing cash flows	(4)	(4)
1.14 Total operating and investing cash flows	(261)	(261)
Cash flows related to financing activities		
1.15 Proceeds from issues of shares	4	4
1.16 Proceeds from sale of forfeited shares	-	-
1.17 Proceeds from borrowings	-	-
1.18 Repayment of borrowings:	-	-
1.19 Dividends paid	-	-
1.20 Other Creditors (costs of fund raising)	-	-
Net financing cash flows	4	4
Net increase (decrease) in cash held	(257)	(257)
1.21 Cash at beginning of quarter/year to date	1213	1213
1.22 Exchange rate adjustments to item 1.20	-	-
1.23 Cash at end of quarter	956	956

+ See chapter 19 for defined terms.

Payments to directors of the entity and associates of the directors

Payments to related entities of the entity and associates of the related entities

		Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	48
1.25	Aggregate amount of loans to the parties included in item 1.11	13

1.26 Explanation necessary for an understanding of the transactions

Payment of director's fees and compulsory superannuation.

Non-cash financing and investing activities

2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

N/A

2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

N/A

Financing facilities available

Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).

	Amount available \$A'000	Amount used \$A'000
3.1 Loan facilities	400	-
3.2 Credit standby arrangements	-	-

+ See chapter 19 for defined terms.

Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.		Current quarter \$A'000	Previous quarter \$A'000
4.1	Cash on hand and at bank	956	1213
4.2	Deposits at call	-	-
4.3	Bank overdraft	-	-
4.4	Other (provide details)	-	-
Total: cash at end of quarter (item 1.23)		956	1213

Acquisitions and disposals of business entities

		Acquisitions	Disposals
5.1	Name of entity	N/A	N/A
5.2	Place of incorporation or registration		
5.3	Consideration for acquisition or disposal		
5.4	Total net assets		
5.5	Nature of business		

Compliance statement

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does give a true and fair view of the matters disclosed.

Sign here:



Date: 31st October 2012

Print name: Ross Mangelsdorf Director, CFO